Results 11 to 20 of about 10,352 (222)

Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

Journal of Allergy and Clinical Immunology: Global, 2023
This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis.
Shuhei Hara, MD, Takaaki Itonaga, MD, Makoto Nishino, MD, Noriyuki Yanagida, MD, PhD, Sakura Sato, MD, Motohiro Ebisawa, MD, PhD   +5 more
doaj   +1 more source

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

BMC Pulmonary Medicine, 2022
Background Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. Methods We retrospectively
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, Shota Fujimoto, Junko Watanabe, Hiromichi Hara, Takanori Numata, Kazuyoshi Kuwano, Yoshinori Matsuwaki   +8 more
doaj   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults

Качественная клиническая практика, 2022
Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin, Y. M. Gomon, M. A. Proskurin, Y. E. Balikina   +3 more
doaj   +1 more source

Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)

International Journal of Women's Dermatology, 2019
Background: The mechanisms underlying eye-related complications with dupilumab are poorly understood. Objective: This study aimed to determine the incidence and characteristics of ocular complications with dupilumab and the prevalence of comorbid ...
Jodie Raffi, BA, Raagini Suresh, BS, Harvey Fishman, MD, PhD, Nina Botto, MD, Jenny E. Murase, MD   +4 more
doaj   +1 more source

Two‐sided influence of dupilumab on alopecia areata co‐existing with severe atopic dermatitis: A case series and literature review

Journal of Cutaneous Immunology and Allergy, 2023
Objectives Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA ...
Masahiro Fukuyama, Misaki Kinoshita‐Ise, Yoshiko Mizukawa, Manabu Ohyama   +3 more
doaj   +1 more source

Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting

JEADV Clinical Practice, 2023
Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations.
Ken Igawa, Hiroyuki Fujita, Yuki Tajima, Robert Lubwama, Moataz Daoud, Zhixiao Wang, Kazuhiko Arima   +6 more
doaj   +1 more source

Unique Features of Nasal Airway and Airflow Improvement Post-Dupilumab: A Computational Cohort Study. [PDF]

Laryngoscope
The impact of dupilumab on nasal airway patency and airflow is not uniform. It is more pronounced in the middle and superior, but not inferior meatus. These unique regional changes significantly correlate with and potentially drive the improvement in patient symptoms.
Odeh A, Wu Z, Jha N, Schneller AR, Mihalich J, Root ZT, Brooks C, Curtis C, Kraft M, Wada K, Otto BA, Kelly KM, Zhao K.   +12 more
europepmc   +2 more sources

Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report

BMC Pulmonary Medicine, 2023
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small-to-medium vessel vasculitis associated ...
Isao Suzaki, Akihiko Tanaka, Ryo Yanai, Yuki Maruyama, Sawa Kamimura, Kojiro Hirano, Hitome Kobayashi   +6 more
doaj   +1 more source

Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis

Journal of Allergy and Clinical Immunology: Global
Background: Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials.
Jayant M. Pinto, MD, Mirko Fillbrunn, PhD, Bruno Martins, PhD, Min Yang, PhD, Chao Chen, PhD, Scott Nash, MD, Mark Corbett, MD, Aakash Gandhi, PhD, Zhixiao Wang, PhD   +8 more
doaj   +1 more source